Amylyx Pharmaceuticals Inc's total assets for Q4 2025 were $332.64M, a decrease of -8.30% from the previous quarter. AMLX total liabilities were $27.39M for the fiscal quarter, a -10.93% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.